GLP-1 Providers That Accept Insurance for Insulin Resistance (2026)
Published:
·13 min readIf you are looking for GLP-1 providers that accept insurance for insulin resistance, here is the truth nobody else on page one wants to say plainly: insulin resistance by itself usually does not get a GLP-1 covered. Not because your condition is not real — it absolutely is — but because "insulin resistance" on a chart usually does not match how insurers define a covered indication for Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo.
That does not mean you are stuck. Three coverage pathways actually work — and the path your doctor uses usually depends on what else is documented in your chart, not the words "insulin resistance" alone.
The shortest version of the answer:
- →Have commercial insurance? Start with Ro's free GLP-1 Insurance Coverage Checker. Enter your insurance-card details and Ro sends a personalized report on what your plan covers and your estimated copay. No payment required.
- →Want visits and labs billed through insurance, or you are on Medicare? Form Health accepts most major commercial plans and Medicare, and bills visits, labs, and medications through insurance.
- →Insurance likely to deny you, or you are a Costco member? Sesame's Costco partnership is a strong FDA-approved cash-pay backstop. Pricing varies by drug and dose.
Ro: sponsored affiliate link. Coverage report is free. No commitment required.
Quick Verdict Table
| If your situation is… | Start here | Why |
|---|---|---|
| Commercial insurance, not sure what is covered | Ro free coverage checker | Verifies medication coverage before you spend a dime |
| Want visits and labs billed through insurance | Form Health or PlushCare | Closer to traditional in-network medical care |
| On Medicare with prediabetes or BMI 27+ and a qualifying condition | Form Health, Knownwell where available, or local clinician | Medicare GLP-1 Bridge starts July 1, 2026 |
| On Medicaid | Your state Medicaid formulary and in-network clinician | Coverage varies by state — no national winner |
| Costco member who wants a cash-pay backstop | Sesame (Success by Sesame) | Costco MPP pricing for Wegovy and Ozempic |
| Already denied by insurance | Identify the denial reason first | Resubmitting the same weak request usually fails again |
| No insurance at all | FDA-approved cash-pay: NovoCare, LillyDirect, or Sesame/Costco | Skip the membership-style telehealth markups |
Not sure which row is yours? Take our free 60-second GLP-1 path quiz →
The Honest Answer: Does Insurance Cover GLP-1 for Insulin Resistance?
Insulin resistance by itself is usually not a covered indication for any FDA-approved GLP-1 medication.
Coverage depends on the medication's FDA-approved use, your plan's formulary, prior-authorization rules, your BMI, and whether your chart documents a recognized diagnosis — type 2 diabetes, obesity, overweight with a weight-related comorbidity, established cardiovascular disease, obstructive sleep apnea (for Zepbound), or — starting July 1, 2026 — Medicare GLP-1 Bridge criteria.
Why "insulin resistance" alone usually fails
Insurers do not approve drugs for symptoms or risk states on their own. They approve drugs for FDA-approved indications. Ozempic is FDA-approved for type 2 diabetes. Wegovy and Zepbound are FDA-approved for chronic weight management. Foundayo (orforglipron) was FDA-approved on April 1, 2026 for adults with obesity or adults with overweight and at least one weight-related comorbidity. None of those indications say "insulin resistance" specifically — and that gap is exactly where prior authorization attempts fail.
41M+
commercially insured Americans lack Wegovy coverage
Source: GoodRx Research
109M+
commercially insured Americans lack Zepbound coverage
Source: GoodRx Research
>88%
of those with weight-loss GLP-1 coverage still face PA or step therapy
Source: GoodRx Research
What this means in plain English
If your chart says “insulin resistance, BMI 24, normal A1C” and nothing else, you will probably get denied.
If your chart says “BMI 31, A1C 5.9% (prediabetes), insulin resistance, and documented prior lifestyle or medication attempts if your plan requires them,” you have a much stronger obesity-pathway case. The difference between approval and denial is often whether your documentation matches the plan's stated criteria — not how much you deserve the medication.
Which ICD-10 Code Matters for Insulin Resistance GLP-1 Coverage?
Insulin resistance ICD-10 codes can support your prior authorization, but they usually should not be the only diagnosis driving it. The relevant path is usually the covered indication first — type 2 diabetes, obesity or overweight with a plan-recognized comorbidity, OSA, cardiovascular risk, or Medicare Bridge criteria — with insulin resistance documented as supporting context.
The October 2024 ICD-10 change worth knowing
As of October 1, 2024, the old single insulin-resistance code (E88.81) was officially split into four more specific codes:
| Code | Meaning | GLP-1 coverage role |
|---|---|---|
| E88.810 | Metabolic Syndrome | Supporting context; cluster often meets obesity pathway |
| E88.811 | Insulin Resistance Syndrome Type A | Rare genetic form — not what most people have |
| E88.818 | Other Insulin Resistance ← most common | Supporting context; not a standalone approved indication |
| E88.819 | Unspecified Insulin Resistance | Supporting context; not a standalone approved indication |
Source: CDC ICD-10-CM Update October 2024
Documented insulin resistance may support an obesity-pathway prior authorization, especially when paired with BMI 27+ plus prediabetes (R73.03), hypertension, dyslipidemia, sleep apnea, or another plan-recognized condition. Do not assume every insurer treats insulin resistance alone as the qualifying comorbidity. The next section shows you the three pathways that actually unlock coverage.
The Three Coverage Pathways That Actually Work
Three diagnosis paths unlock GLP-1 coverage in 2026: the type 2 diabetes pathway, the obesity pathway, and the new Medicare GLP-1 Bridge pathway (live July 1, 2026 through December 31, 2027). The path your doctor uses determines which medication is most likely to be approved.
| Pathway | What you need on your chart | BMI / Lab requirement | Medications most likely covered |
|---|---|---|---|
| A. Type 2 Diabetes | T2D diagnosis (E11.x); A1C 6.5%+ in the diabetes range | A1C 6.5%+ (no BMI threshold) | Ozempic, Mounjaro, Rybelsus, Trulicity |
| B. Obesity / Overweight + Comorbidity | E66.811/812/813 (BMI 30+) — OR BMI 27+ with plan-recognized condition: prediabetes, hypertension, dyslipidemia, sleep apnea, CVD. Insulin resistance supports the case but is not always sufficient alone. | BMI 30+, OR BMI 27+ with a plan-recognized comorbidity | Wegovy, Zepbound, Foundayo, Saxenda |
| C. Medicare GLP-1 Bridge (July 1, 2026 – Dec 31, 2027) | BMI ≥35 alone; OR BMI ≥30 with HFpEF, uncontrolled hypertension, or CKD stage 3a+; OR BMI ≥27 with prediabetes, previous MI, previous stroke, or symptomatic PAD | See left column | Foundayo (all forms), Wegovy injection + tablets, Zepbound KwikPen — $50/month flat copay |
Sources: ADA Standards of Care; FDA labels; CMS Medicare GLP-1 Bridge FAQ (updated April 6, 2026). Numbers cited come from Ro's 2025 GLP-1 Insurance Coverage Checker Report, GoodRx Research, KFF, and CMS where applicable.
Type 2 Diabetes — the path with the broadest coverage
An A1C of 6.5% or higher is in the diabetes range. Clinicians commonly confirm the diagnosis with repeat testing or another diagnostic test unless the clinical picture is already clear. That diagnosis unlocks Ozempic, Mounjaro, Rybelsus, or Trulicity on most commercial plans' standard diabetes-drug benefit, typically after a prior authorization.
Obesity + Comorbidity — the most common path for insulin resistance
This is the pathway that matters most for people searching this page. If your BMI is 30 or higher, you typically qualify on BMI alone. If your BMI is 27–29.9, you usually need at least one plan-recognized weight-related comorbidity. Insulin resistance can support that case, but prediabetes, hypertension, dyslipidemia, sleep apnea, established cardiovascular disease, or another explicitly listed condition often makes the prior authorization stronger.
A few plan examples to check before your provider submits:
· CVS Caremark: GoodRx Research reports CVS Caremark removed Zepbound from its standard formulary in July 2025, making Wegovy the preferred weight-loss GLP-1. Your employer plan may still vary.
· Aetna, Cigna, UnitedHealthcare, BCBS, Kaiser: Use the plan's current PA PDF or member formulary, not a generic rule of thumb. Weight-loss medication coverage varies by employer group, region, and benefit design.
Medicare GLP-1 Bridge — brand new, starts July 1, 2026
Live July 1, 2026 through December 31, 2027 · $50/month flat copayIf you are on Medicare Part D, standard Part D generally does not cover drugs used solely for weight loss. But CMS's Medicare GLP-1 Bridge changes that for eligible beneficiaries. Eligible Bridge products are Foundayo (all formulations), Wegovy (injection and tablets), and Zepbound KwikPen. The pharmacy collects a $50 copay per monthly supply.
CMS eligibility criteria (updated April 6, 2026):
Important CMS caveats:
· The $50 Bridge copay is collected by the pharmacy, does not count toward your TrOOP (true out-of-pocket cap), and low-income cost-sharing subsidies do not apply to the Bridge copay.
· Single-dose vials and single-dose pens of Zepbound are NOT included in the Bridge — only Zepbound KwikPen. Ozempic and Mounjaro are also not in the Bridge (those remain Part D for type 2 diabetes).
Want to know which pathway fits your plan? Ro's free GLP-1 Insurance Coverage Checker runs your plan and gives you a personalized report after you enter your insurance-card details. No payment required.
Check your coverage free →Sponsored affiliate link.Which GLP-1 Providers Accept Insurance for Insulin Resistance?
Seven telehealth routes can help adults with insulin resistance use insurance for a GLP-1 in 2026. We verified each one in May 2026.
| Provider | Best for | Visits/labs billed to insurance? | Medication PA help? | Government plans? | Program cost |
|---|---|---|---|---|---|
| Ro ★ | Commercial insurance + concierge to file PA | No — membership is cash-pay | ✅ Concierge is the headline feature | FEHB yes; Medicare/Tricare cash-pay only; Medicaid cannot join | $39 first month, then as low as $74/mo annual or $149/mo ongoing |
| Form Health | Visits/labs billed through insurance + Medicare | ✅ Yes, for in-network patients | ✅ Yes, as part of care | ✅ Medicare yes | Insurance-billed for many; ~$299/mo self-pay |
| Sesame | Costco-priced cash-pay backstop | No — program is cash-pay | ✅ Providers assist | No special path; Costco MPP requires Costco membership | As low as $59/mo annual; $99/mo monthly |
| PlushCare | Virtual PCP with broad commercial coverage | ✅ Commercial yes; Medicare Part B no longer accepted as of Jan 1, 2026 | ✅ Physicians submit PA | Commercial yes; Medicare Part B no | ~$17/mo + visit copay |
| WeightWatchers Clinic | Medication + behavior/coaching structure | Varies by plan | Yes | Limited | $25 first month with 12-mo plan; then ~$74/mo |
| Found | Free insurance check across many plans/states | Varies by plan/state | Yes | Limited; varies | Varies by plan; medication separate |
| Knownwell | No-membership in-network primary care + obesity medicine | ✅ Yes, where in-network | ✅ Helps with PA + post-denial next steps | Medicare in select states | No membership fee; per-visit or insurance copay |
Why Ro is our pick for most commercial-insurance readers
Ro's GLP-1 Insurance Coverage Checker is free — no payment, no commitment. After you enter your insurance-card information, Ro contacts your insurer, verifies what is covered, identifies whether prior authorization is required, and emails you a personalized report with copay estimates. If you decide to move forward with Ro Body, an insurance concierge handles the prior authorization paperwork on your behalf and continues working with your insurer through approval.
Ro's published data
43% of users had coverage of a GLP-1 for weight loss. Half of covered patients had a copay of $50/month or less. Prior authorization was generally required for coverage.
Source: Ro GLP-1 Insurance Coverage Checker Report, data from Aug 13, 2024 through Apr 17, 2025.
Pricing (verified May 2026)
Get started for $39, then as low as $74/month with annual plan paid upfront, or $149/month ongoing. Medication is billed separately. Labs at Quest Diagnostics included.
Our one damaging admission about Ro:
Ro does NOT bill its membership through your health insurance. The membership is always cash-pay, even when your insurance covers the medication. If billing your visits and labs through insurance is your top priority, Form Health is the better pick — they bill Care Team visits, labs, and medications through most major private insurance plans and Medicare.
Ro cannot coordinate GLP-1 medication coverage for most government insurance plans. FEHB is the exception. Medicaid members cannot join Ro Body at all.
Sponsored affiliate link. Coverage report is free. Does not guarantee insurance approval.
Why Form Health is our pick for Medicare or true in-network billing
Form Health is an obesity-medicine specialty practice that bills Care Team visits, labs, and medications through most major private insurance plans and Medicare. To qualify clinically, you need BMI 30+ or BMI 27+ with a weight-related health risk. Ask Form directly whether your insulin-resistance documentation satisfies its clinical intake criteria.
Care is led by board-certified obesity medicine clinicians, which matters for PA approval because plans typically give more weight to specialty obesity-medicine documentation than to generic PCP notes.
Why Sesame is our pick for a Costco-priced cash-pay backstop
Through Sesame's partnership with Costco and Novo Nordisk, Costco Member Prescription Program (MPP) pricing for Wegovy and Ozempic is dose-specific:
| Medication | Costco MPP cash-pay pricing |
|---|---|
| Wegovy injections | $199/month for first two fills of 0.25 mg or 0.5 mg (through June 30, 2026); then $349/month for 1 mg, 1.7 mg, or 2.4 mg |
| Ozempic | $199/month for first two fills of 0.25 mg or 0.5 mg (through June 30, 2026); $349/month for 1 mg; $499/month for 2 mg |
The Success by Sesame program itself runs as low as $59/month on the annual plan, which includes video visits, labs, messaging, and ongoing oversight.
PlushCare, WeightWatchers Clinic, Found, and Knownwell
PlushCare — for a virtual-PCP experience
In-network with most major commercial insurers. Physicians prescribe Wegovy, Zepbound, Ozempic, and Mounjaro when clinically appropriate and file prior authorization on your behalf. PlushCare no longer accepts Medicare Part B as of January 1, 2026. Membership: ~$17/month plus your insurance copay per visit.
WeightWatchers Clinic — for medication plus behavior coaching
Fits if you want medication access plus WW's coaching structure. Care Team works with insurance to reduce out-of-pocket costs. Pricing: $25 first month with a 12-month plan, then ~$74/month. Medication billed separately.
Found — for a free insurance check
Offers a free insurance check and reports in-network status for “1 in 3 Americans,” with coverage varying state-by-state and plan-by-plan. Useful free-look option if you are not sure who is in-network for you.
Knownwell — for no-membership in-network obesity medicine
Primary-care-meets-obesity-medicine model with no membership fee — you pay per visit or your insurance copay. Accepts many major insurance plans; Medicare and Medicaid availability varies by state. Strong runner-up to Form Health for Medicare beneficiaries where Knownwell operates.
What Diagnosis Gives You the Strongest Insurance Path?
The strongest GLP-1 insurance path almost always involves layering your insulin resistance with a more recognized diagnosis. The order of “easier to cover” generally goes: type 2 diabetes (easiest), obesity with documented comorbidity, prediabetes plus BMI for Medicare Bridge, established cardiovascular disease, obstructive sleep apnea (for Zepbound specifically), and PCOS or metabolic syndrome as supporting context.
If your A1C is in the diabetes range (6.5%+)
You have a strong T2D pathway. Your doctor codes E11.x, prescribes Ozempic, Mounjaro, Rybelsus, or Trulicity, and submits a standard diabetes PA. Approval timing varies by plan — complete documentation moves faster, while denials, missing records, or appeals can take longer. Do not expect Wegovy or Zepbound through this pathway.
If your BMI is 30+ OR 27+ with a weight-related comorbidity ← most common scenario
The obesity pathway covers Wegovy, Zepbound, Foundayo, and Saxenda. PA criteria typically include documented BMI, the comorbidity (your insulin resistance plus prediabetes, hypertension, dyslipidemia, sleep apnea, or another listed condition), and three to six months of supervised lifestyle attempts that did not produce sustained weight loss.
Get your chart right and approval rates are meaningfully higher. Skip a piece of documentation and you may get denied for something fixable.
If you have prediabetes (R73.03)
Prediabetes alone is not a standalone GLP-1 indication on most commercial plans, but it is a key qualifier under the Medicare GLP-1 Bridge when paired with BMI 27+. That combination gets you the $50/month copay on Wegovy, Zepbound KwikPen, or Foundayo starting July 1, 2026. Under 65 with commercial insurance, prediabetes strengthens an obesity-pathway PA — it signals to the insurer that you are sliding toward T2D and the medication is preventive.
If you have PCOS or metabolic syndrome
PCOS is not an FDA-approved indication for any GLP-1, full stop. But research has estimated that insulin resistance affects about 65–70% of women with PCOS overall. Many women with PCOS also qualify under the obesity pathway because PCOS is strongly associated with weight gain. If your BMI is 27+ with PCOS and documented insulin resistance, your provider can submit through the obesity pathway with PCOS noted as supporting context. For a deeper dive, see our Best GLP-1 for PCOS guide.
Metabolic syndrome (E88.810) — a cluster including abdominal obesity, elevated blood pressure, elevated fasting glucose, high triglycerides, and low HDL — typically meets the obesity pathway easily.
If you have obstructive sleep apnea — a back-door pathway most people miss
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity as of December 2024. Many commercial plans — and even some Medicare Part D plans — will cover Zepbound for OSA even when they exclude weight-loss-only use. If you have a sleep study showing OSA and BMI 30+, ask your provider whether the OSA indication is the better PA route for you.
If you have established cardiovascular disease
Wegovy carries an FDA-approved indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or obese. This pathway often gets approved when weight-loss-only would be denied — especially through Medicare Part D, which generally will not cover Wegovy for weight loss alone but can cover it for cardiovascular risk reduction.
Need help figuring out which pathway fits your chart? Take our free 60-second GLP-1 path quiz and we'll route you to the right next step.
Take the free quiz →What to Gather Before a Prior Authorization
Your provider cannot file a strong prior authorization if your chart is thin. The five elements every successful GLP-1 PA contains: current BMI documentation, relevant labs, comorbidity documentation with ICD-10 codes, prior lifestyle attempts, and prior medication trials when your plan's step therapy requires them.
The Document Checklist — save or screenshot this section
The “do not waste the PA” question
Before your provider submits, ask one question: “Which medication and indication are we submitting under?” If your chart only supports an obesity-pathway PA but the prescription is written for Ozempic for off-label insulin resistance, you will likely get denied. If your chart supports prediabetes plus BMI 27+ and you have Medicare, the GLP-1 Bridge pathway will be cheaper than the commercial Wegovy pathway. Get clear before the form goes in.
Have these documents? Do not submit blind. Run Ro's free coverage check before your provider files the PA so you know which medication and indication your plan is likely to evaluate.
Run the free check →Sponsored affiliate link.What If You Have Commercial Insurance?
Commercial insurance is the most realistic online-provider path for adults with insulin resistance, but coverage is plan-specific. The fastest no-risk sequence: check coverage first, identify which medication your plan covers under which indication, gather documentation, then pick a provider that will submit the PA for you.
Run a free coverage check first
Ro's GLP-1 Insurance Coverage Checker, NovoCare's coverage tool, or LillyDirect's eligibility check each tell you whether your plan covers Wegovy, Zepbound, Ozempic, or Mounjaro before you sign up for anything.
Ask for the exact coverage criteria
Call your insurer or pull the prior-authorization criteria PDF. You want to know the BMI threshold, required comorbidities, step-therapy requirements, and documentation list.
Confirm whether weight-loss medications are excluded
Some employer plans (especially smaller self-funded plans) exclude the entire weight-loss medication category. If yours does, the obesity pathway is dead — only the T2D, OSA, or CV pathways can work.
Match medication to your pathway
If you are going T2D, that is Ozempic or Mounjaro. If you are going obesity-pathway, that is Wegovy or Zepbound. Trying to get the wrong medication approved for the wrong indication wastes weeks.
Complete the provider intake fully
Do not skip the lifestyle history or prior-medications section. That is the data the PA will hinge on.
Upload all your documentation before the PA goes in
Photos of insurance cards, recent lab PDFs, medication history, weight history. Missing documentation is the most common reason GLP-1 PAs get denied.
Check your plan with Ro before you pay for treatment — the coverage report tells you which medication is covered and your estimated copay.
Run the free check →Sponsored affiliate link.What If You Have Medicare?
Medicare standard Part D generally does not cover drugs when used solely for weight loss, but CMS's Medicare GLP-1 Bridge changes that on July 1, 2026 for eligible beneficiaries. Bridge coverage is $50/month flat copay for Wegovy, Zepbound KwikPen, and Foundayo, runs through December 31, 2027, and requires CMS-defined BMI plus qualifying-condition criteria.
Eligibility criteria for the Bridge (per CMS, updated April 6, 2026)
You qualify if you are enrolled in an eligible Medicare Part D plan, AND:
Eligible medications only: Foundayo (all forms), Wegovy injection and tablets, Zepbound KwikPen only. Ozempic and Mounjaro are NOT in the Bridge. Single-dose Zepbound vials and pens are NOT included.
Copay caveat: The $50 Bridge copay does NOT count toward your TrOOP, and CMS says low-income cost-sharing subsidies do not apply to the Bridge copay.
Which provider to use for Medicare:
- · Do not start with a commercial-insurance concierge if you are on Medicare. Ro cannot coordinate GLP-1 medication coverage for most government plans (FEHB is the exception).
- · Form Health — accepts Medicare, obesity-medicine specialty, the cleanest verified national Medicare path.
- · Knownwell — also accepts Medicare in select states, no membership fee.
- · Your local PCP or endocrinologist — if they are willing to file the Bridge PA, your cost is your usual Medicare copay plus the Bridge $50.
What If You Have Medicaid?
Medicaid coverage for GLP-1s varies by state, and most national cash-pay telehealth programs are not designed for Medicaid patients. As of January 2026, KFF reported that 13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service, typically with utilization controls such as prior authorization. Most state Medicaid programs cover GLP-1s for type 2 diabetes.
Why we do not recommend a national Medicaid winner:
The right answer literally changes state by state. Ro Body specifically does not accept Medicaid patients. Sesame's program is cash-pay. Form Health and Knownwell may or may not be in-network with your specific state Medicaid plan.
The right move for Medicaid:
- Call your Medicaid plan and ask: “Do you cover Wegovy, Zepbound, or Ozempic for [your diagnosis]? What is the prior-authorization criteria?”
- Check your state Medicaid formulary online — most states publish their preferred drug list.
- Find an in-network clinician (your PCP or a Medicaid-accepting obesity-medicine specialist) who will handle the PA.
- If your state does not cover weight-loss GLP-1s and you do not have T2D, your realistic options are appeal, manufacturer patient-assistance programs (Novo Nordisk and Eli Lilly both have income-based assistance), or FDA-approved cash-pay routes.
Medicaid and insulin resistance is a state-by-state puzzle. Take our free 60-second quiz and we will give you a state-specific next-step checklist.
Take the free quiz →What If Insurance Denies Your GLP-1?
A denial is not automatically the end. Your next step is to read the denial reason, identify whether the issue is exclusion, diagnosis mismatch, missing documentation, or step therapy, and decide whether to appeal, resubmit with corrected documentation, switch to a different FDA-approved indication, or use a cash-pay fallback. You typically have 180 days from the denial letter to file an internal appeal — check your specific letter for the exact deadline.
Why most insulin-resistance denials happen
The 4 elements of a strong appeal
The denial letter itself
Read it carefully — it states the exact reason, the appeal deadline, and the documentation required. Do not skip this.
A Letter of Medical Necessity from your provider
This is the heart of the appeal. It should cite your BMI, your comorbidities, the FDA-approved indication you qualify for, your prior treatments, and the clinical guidelines supporting the medication for your situation.
All the labs and chart notes that were missing the first time
If your plan wanted six months of lifestyle attempts and your first submission only had three months, get the additional notes.
A peer-to-peer review request (where appropriate)
Your provider speaks directly to the insurer's medical director, who has authority to overturn the denial on the call. Often worth requesting — especially for second-level appeals.
External review
If your insurer denies the internal appeal, your denial letter should explain whether external review is available and how to request it. Timelines and eligibility vary by plan type and state.
Already denied? Do not resubmit the same weak request. If you have commercial insurance, use a provider that helps with coverage paperwork and prior authorization.
Ro: sponsored affiliate link.
What If You Pay Cash? FDA-Approved Routes to Compare Before Compounded
If insurance denies you completely, FDA-approved cash-pay routes are worth comparing before you go anywhere near compounded. The options below are FDA-approved medications, not compounded formulations. Pricing varies by drug, dose, and the specific savings program — verify before you commit.
| Route | Medication | Price (current published) |
|---|---|---|
| Wegovy pill (NovoCare) | Wegovy 1.5 mg or 4 mg tablet | $149/month for 1.5 mg and 4 mg; the 4 mg offer available through August 31, 2026, then $199/month for 4 mg |
| Ozempic via Costco MPP | Ozempic | $199/month for first two fills of 0.25 mg or 0.5 mg through June 30, 2026; $349/month for 1 mg; $499/month for 2 mg |
| Wegovy injection via Costco MPP | Wegovy injection | $199/month for first two fills of 0.25 mg or 0.5 mg through June 30, 2026; $349/month for 1 mg, 1.7 mg, or 2.4 mg |
| LillyDirect Zepbound (Self Pay Journey) | Zepbound vials | $299/month for 2.5 mg; $399/month for 5 mg; $449/month for 7.5 mg, 10 mg, 12.5 mg, or 15 mg |
| Foundayo via Ro | Foundayo (orforglipron) | $149 for the first month; $199–$299/month thereafter depending on dose |
| Foundayo via Sesame | Foundayo (orforglipron) | $149/month for 0.8 mg; $199/month for 2.5 mg; $299/month for 5.5 mg or 9 mg; $349/month for 14.5 mg or 17.2 mg |
Some manufacturer savings programs may reduce costs further for commercially insured patients who meet program terms. Medicare, Medicaid, and other government-program beneficiaries are typically excluded from manufacturer savings cards. All prices verified May 2026.
A compliance note on compounded GLP-1s
You will see compounded semaglutide and tirzepatide at $99–$269/month from various telehealth providers. We are not recommending compounded for this page, for one important reason: compounded GLP-1 medications are not FDA-approved as finished products. The FDA does not review compounded drugs for safety, effectiveness, or quality the way it reviews brand-name medications.
If you have exhausted FDA-approved cash-pay routes and want to explore compounded for cost reasons, see our guide on GLP-1 options without insurance. On this page — about insurance coverage — compounded is not the answer to your search.
How Much It Actually Costs (All-In)
The program fee and the medication cost are almost always separate. This is where most people get surprised: a provider may help with insurance for the medication while the membership itself stays cash-pay.
| Route | Program/visit fee | Medication with insurance | Medication cash-pay backstop |
|---|---|---|---|
| Ro Body + commercial insurance covers GLP-1 | $74–$149/mo membership | Plan copay; savings cards may reduce further for eligible commercial patients | Wegovy/Zepbound cash-pay through Ro: ranges by drug and dose |
| Form Health in-network | Insurance copay per visit (labs and meds separate) | Plan copay; savings cards where eligible | $299/mo Form Health self-pay (medication separate) |
| Sesame + Costco | $59–$99/mo for Sesame program | Plan copay if PA approved | Costco MPP dose-specific pricing |
| PlushCare in-network | ~$17/mo + visit copay | Plan copay; savings cards where eligible | Retail pharmacy cash-pay varies |
| Knownwell | No membership; visit copay | Plan copay; savings cards where eligible | Retail cash-pay varies |
For commercial-insurance readers with a stacked savings card, Form Health, PlushCare, and Knownwell often come in cheapest because there is no recurring membership fee on top of medication. Ro is more expensive on the membership side, but its concierge handles all the PA work that in-network providers may or may not push as hard on. The right pick depends on whether your time or your money is the bottleneck.
Which Path Should You Choose?
Choose by insurance type first, diagnosis second, provider model third. If you pick by brand familiarity alone, you may waste a signup on a provider whose model does not match what you need.
| Your situation | Start here | If that fails |
|---|---|---|
| Commercial insurance, BMI 30+ or 27+ with a comorbidity | Ro free coverage check → if covered, Ro Body files PA | Form Health in-network billing |
| Commercial insurance, want visits billed in-network | Form Health or PlushCare | Sesame/Costco cash-pay backstop |
| Commercial insurance, A1C 6.5%+ | Any provider — T2D pathway is generally easier to approve | — |
| Medicare 65+, BMI 27+ with prediabetes/CVD/PAD | Form Health or local clinician → file Medicare Bridge PA on/after July 1, 2026 | NovoCare or LillyDirect cash-pay |
| Medicare 65+, BMI 35+ alone | Same — Bridge pathway | Same |
| Medicaid | Call your state Medicaid plan first; find in-network clinician | Manufacturer patient assistance + appeal |
| Tricare or FEHB | Ro Body works for FEHB; Tricare cash-pay only | NovoCare or LillyDirect cash-pay |
| Uninsured | LillyDirect ($299–$449), Wegovy pill ($149), or Sesame/Costco | — |
| Already denied once | Identify the denial reason; appeal with corrected documentation | Switch indication (e.g., OSA path for Zepbound) |
| PCOS + insulin resistance, BMI under 27 | See our Best GLP-1 for PCOS guide | LillyDirect or NovoCare cash-pay |
Not sure which row is yours? Take our free 60-second GLP-1 path quiz and we will route you to the right next step.
Take the quiz →How We Built This Page
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We built this page by walking through every provider's official insurance, pricing, and program pages, the CMS Medicare GLP-1 Bridge FAQ, the FDA prescribing information for each medication, the October 2024 ICD-10-CM updates, GoodRx Research's coverage tracker, KFF's Medicaid GLP-1 data, and publicly available formulary policies from major insurers.
What we verified (May 2026)
- ✅Provider pricing for Ro, Sesame, Form Health, PlushCare, WeightWatchers Clinic, Found, and Knownwell — from each provider's official site
- ✅Each provider's insurance model (visit billing vs medication coverage support vs cash-pay)
- ✅Medicare GLP-1 Bridge eligibility criteria and eligible drugs — from cms.gov, updated April 6, 2026
- ✅October 2024 ICD-10 code changes for insulin resistance (E88.81 split) — confirmed against CDC ICD-10-CM update
- ✅FDA-approved indications for Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda, and Rybelsus
- ✅CVS Caremark Zepbound formulary removal (July 2025) — confirmed via GoodRx Research
- ✅Ro's published GLP-1 Insurance Coverage Checker Report data
- ✅KFF's January 2026 Medicaid obesity GLP-1 coverage data (13 state fee-for-service programs)
- ✅Costco Member Prescription Program pricing, LillyDirect Self Pay Journey pricing, NovoCare Wegovy pill pricing
What we did not verify
- · Your specific plan's coverage — that requires running a free coverage check with your actual insurance information
- · Your individual approval — coverage decisions are made plan-by-plan, chart-by-chart
- · Every unpublished insurer PA criterion — these vary by plan and change frequently
- · Provider network status in every state — verify with the provider before booking
Real Member Stories
Quoted from Ro's public GLP-1 Insurance Coverage Checker Report. Ro labels these member stories as paid partners. Individual results vary; these testimonials do not prove typical outcomes, medical efficacy, safety, or insurance approval.
“I could have gone with anyone else, but Ro just spoke to me. It felt like, ‘We're here for you.’ I initially thought I had to pay $1,000 for my medication so I sat on starting my journey for a couple of months. I decided to reach out to Ro to see if the medication cost could be lowered. Within two days, Ro ran my prior authorization and guided me to a savings card. When I went to CVS to pick up my prescription, it was just $25.”
Source: Ro GLP-1 Insurance Coverage Checker Report. Ro identifies this as a paid partner story.
“Before I started taking GLP-1 medication through Ro, I was prediabetic and on my way toward Type 2 diabetes. My weight was out of control, and I had struggled for many years to bring it down — with little success. I joined Ro because I had seen friends living with Type 2 diabetes lose weight, lower their A1c levels, and get a new chance at a healthier, happier life with GLP-1s.”
Source: Ro GLP-1 Insurance Coverage Checker Report. Ro identifies this as a paid partner story.
Frequently Asked Questions
Does insurance cover GLP-1 for insulin resistance?
Usually not for insulin resistance alone. Coverage is more likely when your provider documents a recognized indication — type 2 diabetes (A1C 6.5%+), obesity or overweight with a plan-recognized weight-related comorbidity (BMI 30+, or 27+ with prediabetes, hypertension, dyslipidemia, sleep apnea, or established CVD), or — starting July 1, 2026 — Medicare GLP-1 Bridge criteria.
Can I get Ozempic covered for insulin resistance if I don't have diabetes?
Usually no. Ozempic is FDA-approved for type 2 diabetes, with additional cardiovascular and kidney indications in certain T2D populations. Off-label use for insulin resistance alone is rarely covered. If your A1C is in the prediabetes range (5.7–6.4%) and your BMI is 27+, the more realistic path is Wegovy or Zepbound through the obesity pathway, with insulin resistance documented as supporting context.
Can I get Wegovy or Zepbound covered for insulin resistance?
Possibly. Wegovy and Zepbound coverage is more realistic if your BMI is 30+, or if your BMI is 27+ and your plan recognizes a weight-related comorbidity in your chart. Insulin resistance may support the case, but your plan may require a more specific diagnosis such as prediabetes, hypertension, dyslipidemia, OSA, cardiovascular disease, or another listed condition.
Is prediabetes better than insulin resistance for getting GLP-1 covered?
Often yes. Prediabetes (R73.03, A1C 5.7–6.4%) is a more defined diagnostic category and appears explicitly in some coverage criteria. The 2026 Medicare GLP-1 Bridge specifically lists BMI 27+ with prediabetes as an eligibility route. For commercial plans, prediabetes plus BMI 27+ usually strengthens an obesity-pathway prior authorization.
What is the ICD-10 code for insulin resistance in 2026?
As of October 1, 2024, the old E88.81 was split into four codes: E88.810 (Metabolic Syndrome), E88.811 (Insulin Resistance Syndrome Type A — a rare genetic form), E88.818 (Other insulin resistance), and E88.819 (Unspecified insulin resistance). Most common insulin resistance is coded E88.818 or E88.819. Neither is a standalone covered indication for a GLP-1 — the prior authorization usually needs to lead with the FDA-approved indication, with insulin resistance as supporting context.
Which GLP-1 telehealth provider should I try first?
For commercial insurance, start with Ro's free coverage check, then the insurance concierge files the prior authorization if you continue. For Medicare or in-network visit billing, use Form Health. For the lowest-cost FDA-approved cash-pay backstop, Sesame plus Costco Member Prescription Program pricing. For PCP-style virtual care with broad commercial insurance, PlushCare.
Does Ro accept insurance?
Ro helps with medication insurance coverage and prior authorization for FDA-approved GLP-1s, but the Ro Body membership itself is cash-pay and not billed through insurance. Ro currently cannot coordinate medication coverage for most government insurance plans except FEHB. Medicaid members cannot join Ro Body.
Does Sesame accept insurance?
Sesame's Success by Sesame program runs as cash-pay (as low as $59 per month annual). Sesame providers can assist with medication prior authorization to your insurer. Costco members can fill Wegovy and Ozempic at Costco Pharmacy at dose-specific Member Prescription Program pricing regardless of insurance status.
How long does prior authorization take?
Approval timing varies by plan. Some prior authorizations move in several business days when documentation is complete; denials, missing records, or appeals can take longer. Ro, Form Health, Sesame, PlushCare, and Knownwell all submit on your behalf.
Can I appeal a GLP-1 denial?
Yes. A denial is not automatically the end. Read the denial reason, identify whether the issue is exclusion, diagnosis mismatch, missing documentation, or step therapy, then decide whether to appeal, resubmit with corrected documentation, switch indication, or use a cash-pay fallback. You typically have 180 days from the denial letter to file an internal appeal — check your specific letter for the exact deadline.
Are compounded GLP-1s covered by insurance?
No. Compounded GLP-1 medications are not FDA-approved as finished products and insurance does not cover them. If you go that route, it is cash-pay only. FDA-approved cash-pay alternatives such as NovoCare, LillyDirect, and Sesame/Costco are recommended before compounded for this reason.
Does Medicare cover GLP-1 for insulin resistance?
Standard Medicare Part D generally does not cover drugs when used solely for weight loss. Starting July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy (injection and tablets), Zepbound KwikPen, and Foundayo at a $50 per month flat copay for eligible beneficiaries meeting the CMS BMI plus qualifying-condition criteria. The Bridge runs through December 31, 2027. Ozempic remains covered under standard Part D for type 2 diabetes.
What if my employer plan excludes weight-loss medications?
Three options: (1) Check whether your employer offers a weight-loss medication rider you can add at open enrollment. (2) Check whether the type 2 diabetes pathway, OSA pathway, or cardiovascular risk pathway applies — these often work even when the weight-loss pathway is excluded. (3) Use an FDA-approved cash-pay route such as NovoCare, LillyDirect, or Sesame/Costco until your coverage changes.
Still Not Sure Which Path Fits You?
Most readers on this page have commercial insurance, a BMI in the 27–35 range, and at least one weight-related condition alongside their insulin resistance. For that majority, the right first move is Ro's free GLP-1 Insurance Coverage Checker. But if your situation is different — Medicare, Medicaid, already denied, BMI under 27, no insurance at all — the right next step changes.
Take our free 60-second matching quiz and we will route you to the right provider, the right pathway, and the right documentation checklist for your situation.
Quiz: no signup, no email required. Ro: sponsored affiliate link.
Sources and Verification
- · Ro GLP-1 Insurance Coverage Checker and 2025 Report: ro.co/weight-loss/glp1-insurance-checker/, ro.co/weight-loss/coverage-checker-report/
- · Ro Body pricing and insurance policies: ro.co/weight-loss/pricing/, ro.co/weight-loss/insurance/ (verified May 2026)
- · Sesame Success by Sesame program: sesamecare.com; Sesame + Costco partnership: sesamecare.com/blog/costco-half-price-ozempic-wegovy
- · Costco Member Prescription Program: costco.com/member-prescription-program.html
- · Form Health insurance and Medicare acceptance: formhealth.co/faqs (verified May 2026)
- · PlushCare insurance and weight-loss program: plushcare.com (verified May 2026)
- · WeightWatchers Clinic: weightwatchers.com/us/weight-loss-medication · Found: joinfound.com · Knownwell: knownwell.co
- · CMS Medicare GLP-1 Bridge FAQ: cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (updated April 6, 2026)
- · KFF Medicaid Coverage of and Spending on GLP-1s: kff.org · KFF on the BALANCE Model and Medicare GLP-1 Bridge: kff.org/medicare/
- · FDA on compounded vs FDA-approved drugs: fda.gov
- · FDA approval of Foundayo (orforglipron): FDA press release, April 2026
- · GoodRx Research 2025–2026 commercial coverage tracker: goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
- · NovoCare Wegovy pill pricing: novocare.com · LillyDirect Zepbound Self Pay Journey: lilly.com
- · ADA Standards of Care, Diagnosis and Classification of Diabetes: diabetesjournals.org/care
- · CDC ICD-10-CM Update October 2024 — splitting E88.81 into E88.810/811/818/819
- · NIDDK on insulin resistance and prediabetes: niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
- · Peer-reviewed reference on insulin resistance prevalence in PCOS: PMC PMC3277302
- · FDA Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda, Rybelsus prescribing information: accessdata.fda.gov
Last verified: May 18, 2026. Pricing, formulary policies, and the Medicare GLP-1 Bridge program details change frequently in 2026. We re-verify this page monthly. If you spot something that has changed, contact us at editorial@therxindex.com.
The RX Index is an independent pricing intelligence and comparison resource for GLP-1 telehealth providers. We earn affiliate commissions when readers sign up with certain providers through our links — including Ro, Sesame, Form Health, and others. Our editorial recommendations are based on fit for the search intent and verified facts about each provider, not affiliate payout. Affiliate relationships do not change which provider we recommend or the editorial content of this page.
This page is not medical advice. Consult a licensed clinician before starting any GLP-1 medication. GLP-1 medications carry serious side effects and contraindications, including a boxed warning for personal or family history of medullary thyroid cancer or MEN-2. Read the FDA prescribing information for any medication you are considering.
Written and verified by The RX Index Editorial Team ·
Published:
Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.